Fate of paclitaxel lipid nanocapsules in intestinal mucus in view of their oral delivery

International Journal of Nanomedicine

Volumn 8, Issue , 2013, Pages 4291-4302

  Groo, Anne Claire ^a,b   Saulnier, Patrick ^a   Gimel, Jean Christophe ^a   Gravier, Julien ^c   Ailhas, Caroline ^b   Benoit, Jean Pierre ^a,d   Lagarce, Frederic ^a,d  

^a UNIVERSITÉ D'ANGERS   (France)

^b Grand Quevilly ^*  (France)

^c INSTITUT ALBERT BONNIOT   (France)

^d ANGERS UNIVERSITY HOSPITAL   (France)

Author keywords

Bioavailability; Diffusion; Drug absorption; Mucin; Nanoparticles

Indexed keywords

LIPID; MACROGOL; NANOCAPSULE; NANOCARRIER; PACLITAXEL; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; TRIOCTANOIN;

ANIMAL TISSUE; ARTICLE; BLOOD RHEOLOGY; DIFFUSION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; ENCAPSULATION; FLUORESCENCE RESONANCE ENERGY TRANSFER; INTESTINAL MUCUS; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MUCUS; MUCUS SECRETION; NONHUMAN; PHYSICAL CHEMISTRY; SWINE; TRANSCYTOSIS; VISCOMETRY; WATER CONTENT;

BIOAVAILABILITY; DIFFUSION; DRUG ABSORPTION; MUCIN; NANOPARTICLES;

ANIMALS; DIFFUSION; DRUG STABILITY; INTESTINE, SMALL; LIPIDS; MUCUS; NANOCAPSULES; PACLITAXEL; SWINE; VISCOSITY;

EID: 84887371418     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S51837     Document Type: Article

References (46)

1. Peltier S, Oger JM, Lagarce F, Couet W, Benoît JP. Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded lipid nanocapsules. Pharm Res. 2006;23(6):1243-1250.
2. Heurtault B, Saulnier P, Pech B, Proust JE, Benoit JP. A novel phase inversion-based process for the preparation of lipid nanocarriers. Pharm Res. 2002;19(6):875-880.
3. Allard E, Huynh NT, Vessières A, et al. Dose effect activity of ferrocifen-loaded lipid nanocapsules on a 9L-glioma model. Int J Pharm. 2009;379(2):317-323.
4. Hureaux J, Lagarce F, Gagnadoux F, Clavreul A, Benoit JP, Urban T. The adaptation of lipid nanocapsule formulations for blood administration in animals. Int J Pharm. 2009;379(2):266-269.
5. Roger E, Lagarce F, Benoit JP. The gastrointestinal stability of lipid nanocapsules. Int J Pharm. 2009;379(2):260-265.
6. Roger E, Lagarce F, Garcion E, Benoit JP. Lipid nanocarriers improve paclitaxel transport throughout human intestinal epithelial cells by using vesicle-mediated transcytosis. J Control Release. 2009;140(2):174-181.
7. Roger E, Lagarce F, Garcion E, Benoit JP. Reciprocal competition between lipid nanocapsules and P-gp for paclitaxel transport across Caco-2 cells. Eur J Pharm Sci. 11, 2010;40(5):422-429.
8. Lamprecht A, Benoit JP. Etoposide nanocarriers suppress glioma cell growth by intracellular drug delivery and simultaneous P-glycoprotein inhibition. J Control Release. 2006;112(2):208-213.
9. Morille M, Montier T, Legras P, et al. Long-circulating DNA lipid nanocapsules as new vector for passive tumor targeting. Biomaterials. 2010;31(2):321-329.
10. Roger E, Lagarce F, Garcion E, Benoit JP. Biopharmaceutical parameters to consider in order to alter the fate of nanocarriers after oral delivery. Nanomedicine (Lond). 2010;5(2):287-306.
11. Larhed AW, Artursson P, Gråsjö J, Björk E. Diffusion of drugs in native and purified gastrointestinal mucus. J Pharm Sci. 1997;86(6):660-665.
12. Lai SK, O'Hanlon DE, Harrold S, et al. Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus. Proc Natl Acad Sci U S A. 2007;104(5):1482-1487.
13. Griffiths PC, Occhipinti P, Morris C, Heenan RK, King SM, Gumbleton M. PGSE-NMR and SANS studies of the interaction of model polymer therapeutics with mucin. Biomacromolecules. 2010;11(1):120-125.
14. Grübel P, Cave DR. Factors affecting solubility and penetration of clarithromycin through gastric mucus. Aliment Pharmacol Ther. 1998;12(6):569-576.
15. Hosseinzadeh H, Atyabi F, Dinarvand R, Ostad SN. Chitosan-Pluronic nanoparticles as oral delivery of anticancer gemcitabine: preparation and in vitro study. Int J Nanomedicine. 2012;7:1851-1863.
16. Larhed AW, Artursson P, Björk E. The influence of intestinal mucus components on the diffusion of drugs. Pharm Res. 1998;15(1):66-71.
17. Zabaleta V, Ponchel G, Salman H, Agüeros M, Vauthier C, Irache JM. Oral administration of paclitaxel with pegylated poly(anhydride) nanoparticles: permeability and pharmacokinetic study. Eur J Pharm Biopharm. 2012;81(3):514-523.
18. Agüeros M, Ruiz-Gatón L, Vauthier C, et al. Combined hydroxypropyl-beta-cyclodextrin and poly(anhydride) nanoparticles improve the oral permeability of paclitaxel. Eur J Pharm Sci. 2009;38(4):405-413.
19. Jin Y, Song Y, Zhu X, Zhou D, Chen C, Zhang Z, Huang Y. Goblet cell-targeting nanoparticles for oral insulin delivery and the influence of mucus on insulin transport. Biomaterials. 2012;33(5):1573-1582.
20. Lesuffleur T, Barbat A, Luccioni C, et al. Dihydrofolate reductase gene amplification-associated shift of differentiation in methotrexate-adapted HT-29 cells. J Cell Biol. 1991;115(5):1409-1418.
21. Lesuffleur T, Porchet N, Aubert JP, et al. Differential expression of the human mucin genes MUC1 to MUC5 in relation to growth and differentiation of different mucus-secreting HT-29 cell subpopulations. J Cell Sci. 1993;106(Pt 3):771-783.
22. Meaney C, O'Driscoll C. Mucus as a barrier to the permeability of hydrophilic and lipophilic compounds in the absence and presence of sodium taurocholate micellar systems using cell culture models. Eur J Pharm Sci. 1999;8(3):167-175.
23. Walter E, Janich S, Roessler BJ, Hilfinger JM, Amidon GL. HT29-MTX/Caco-2 cocultures as an in vitro model for the intestinal epithelium: in vitro-in vivo correlation with permeability data from rats and humans. J Pharm Sci. 1996;85(10):1070-1076.
24. Wikman-Larhed A, Artursson P. Co-cultures of human intestinal goblet (HT29-H) and absorptive (Caco-2) cells for studies of drug and peptide absorption. Eur J Pharm Sci. 1995;3(3):171-183.
25. Prego C, Fabre M, Torres D, Alonso MJ. Efficacy and mechanism of action of chitosan nanocapsules for oral peptide delivery. Pharm Res. 2006;23(3):549-556.
26. Behrens I, Pena AI, Alonso MJ, Kissel T. Comparative uptake studies of bioadhesive and non-bioadhesive nanoparticles in human intestinal cell lines and rats: the effect of mucus on particle adsorption and transport. Pharm Res. 2002;19(8):1185-1193.
27. Lundin PD, Bojrup M, Ljusberg-Wahren H, Weström BR, Lundin S. Enhancing effects of monohexanoin and two other medium-chain glyceride vehicles on intestinal absorption of desmopressin (dDAVP). J Pharmacol Exp Ther. 1997;282(2):585-590.
28. Jain S, Kumar D, Swarnakar NK, Thanki K. Polyelectrolyte stabilized multilayered liposomes for oral delivery of paclitaxel. Biomaterials. 2012;33(28):6758-6768.
29. Ezpeleta I, Arangoa MA, Irache JM, et al. Preparation of Ulex europaeus lectin-gliadin nanoparticle conjugates and their interaction with gastrointestinal mucus. Int J Pharm. 1999;191(1):25-32.
30. Bhat PG, Flanagan DR, Donovan MD. The limiting role of mucus in drug absorption: Drug permeation through mucus solution. International Journal of Pharmaceutics. December 29, 1995;126(1-2):179-187.
31. Shaw LR, Irwin WJ, Grattan TJ, Conway BR. The influence of excipients on the diffusion of ibuprofen and paracetamol in gastric mucus. Int J Pharm. 2005;290(1-2):145-154.
32. Bravo-Osuna I, Vauthier C, Chacun H, Ponchel G. Specific permeability modulation of intestinal paracellular pathway by chitosan-poly(isobutylcyanoacrylate) core-shell nanoparticles. Eur J Pharm Biopharm. 2008;69(2):436-444.
33. Norris DA, Sinko PJ. Effect of size, surface charge, and hydrophobicity on the translocation of polystyrene microspheres through gastrointestinal mucin. J Appl Polymer Sci. 1997;63(11):1481-1492.
34. McGill SL, Smyth HD. Disruption of the mucus barrier by topically applied exogenous particles. Mol Pharm. 2010;7(6):2280-2288.
35. Saltzman WM, Radomsky ML, Whaley KJ, Cone RA. Antibody diffusion in human cervical mucus. Biophys J. 1994;66(2 Pt 1): 508-515.
36. Kowapradit J, Apirakaramwong A, Ngawhirunpat T, Rojanarata T, Sajomsang W, Opanasopit P. Methylated N-(4-N, N-dimethylaminobenzyl) chitosan coated liposomes for oral protein drug delivery. Eur J Pharm Sci. 29, 2012;47(2):359-366.
37. Chakravarthi SS, Robinson DH. Enhanced cellular association of paclitaxel delivered in chitosan-PLGA particles. Int J Pharm. 2011;409(1-2):111-120.
38. Artursson P, Karlsson J. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem Biophys Res Commun. 1991;175(3): 880-885.
39. Artursson P, Borchardt RT. Intestinal drug absorption and metabolism in cell cultures: Caco-2 and beyond. Pharm Res. 1997;14(12): 1655-1658.
40. Larhed AW, Artursson P, Björk E. The influence of intestinal mucus components on the diffusion of drugs. Pharm Res. 1998;15(1):66-71.
41. Lai SK, Wang YY, Hanes J. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv Drug Deliv Rev. 2009;61(2): 158-171.
42. Cone RA. Barrier properties of mucus. Adv Drug Deliv Rev. 2009; 61(2):75-85.
43. Hirsjärvi S, Dufort S, Gravier J, et al. Influence of size, surface coating and fine chemical composition on the in vitro reactivity and in vivo biodistribution of lipid nanocapsules versus lipid nanoemulsions in cancer models. Nanomedicine. 2013;9(3):375-387.
44. Chen XM, Elisia I, Kitts DD. Defining conditions for the co-culture of Caco-2 and HT29-MTX cells using Taguchi design. J Pharmacol Toxicol Methods. 2010;61(3):334-342.
45. Broughton-Head VJ, Smith JR, Shur J, Shute JK. Actin limits enhancement of nanoparticle diffusion through cystic fibrosis sputum by mucolytics. Pulm Pharmacol Ther. 2007;20(6):708-717.
46. Hirsjärvi S, Sancey L, Dufort S, et al. Effect of particle size on the biodistribution of lipid nanocapsules: Comparison between nuclear and fluorescence imaging and counting. Int J Pharm. 2013;453(2):594-600.